Weijie Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weijie Qin has a total of 304 co-authors. Here are the top co-authors by number of shared publications:
Wanjun Zhang
State Key Laboratory of Proteomics, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China
34 shared publicationsXiaohong Qian
30 shared publications- Xiaohong Qian
State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of lifeomics, Beijing, China
17 shared publications Yangjun Zhang
State Key Laboratory of Proteomics, Beijing Institute of Lifeomics, National Center for Protein Sciences Beijing, Beijing Proteome Research Center, Beijing, 102206, PR China
16 shared publicationsTong Liu
State Key Laboratory of Medical Proteomics
13 shared publicationsHaihong Bai
School of Basic Medical Science, Anhui Medical University, Hefei, China
11 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Springer Nature in Cell Death & Disease
Arginine methylation coordinates with phosphorylation to control NADP+ synthesis
The NAD(H)/NADP(H) ratio is essential for maintaining cellular redox homeostasis. NAD kinase (NADK) is the sole cytosolic enzyme responsible for converting NAD + to NADP + . Dysregulation of NADK has been linked to aging and cancer; however, the underlying regulatory mechanisms remain poorly understood. Here, we show that NADP + synthesis is markedly suppressed in mice fed a high-fat diet. Mechanistically, NADK undergoes PRMT6-mediated arginine methylation at residues R39, R41, and R45, which inhibits its kinase activity and reduces NADP + production. Mutations at these sites enhance cancer cell proliferation and tumor growth. PRMT6-dependent methylation antagonizes Akt-mediated phosphorylation to inhibit NADK activity by promoting an autoinhibitory function within its N-terminal region, thereby inhibiting NADP + synthesis. In addition, PRMT6 can suppress NADK activity in a phosphorylation-independent manner. NADK methylation is further upregulated by the RB1/E2F pathway in response to a high-fat diet. In hepatocellular carcinoma, reduced NADK methylation elevates NADP + levels and facilitates tumor progression. Collectively, these findings elucidate a regulatory mechanism governing NAD(H)/NADP(H) homeostasis and identify the PRMT6–NADK axis as a critical mediator of cellular adaptation to high-fat diets and increased adiposity.
- 3 September 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessArginine methylation coordinates with phosphorylation to control NADP+ synthesis
The NAD(H)/NADP(H) ratio is essential for maintaining cellular redox homeostasis. NAD kinase (NADK) is the sole cytosolic enzyme responsible for converting NAD + to NADP + . Dysregulation of NADK has been linked to aging and cancer; however, the underlying regulatory mechanisms remain poorly understood. Here, we show that NADP + synthesis is markedly suppressed in mice fed a high-fat diet. Mechanistically, NADK undergoes PRMT6-mediated arginine methylation at residues R39, R41, and R45, which inhibits its kinase activity and reduces NADP + production. Mutations at these sites enhance cancer cell proliferation and tumor growth. PRMT6-dependent methylation antagonizes Akt-mediated phosphorylation to inhibit NADK activity by promoting an autoinhibitory function within its N-terminal region, thereby inhibiting NADP + synthesis. In addition, PRMT6 can suppress NADK activity in a phosphorylation-independent manner. NADK methylation is further upregulated by the RB1/E2F pathway in response to a high-fat diet. In hepatocellular carcinoma, reduced NADK methylation elevates NADP + levels and facilitates tumor progression. Collectively, these findings elucidate a regulatory mechanism governing NAD(H)/NADP(H) homeostasis and identify the PRMT6–NADK axis as a critical mediator of cellular adaptation to high-fat diets and increased adiposity.
- Open Access
- 10 June 2026
- Published by Springer Nature in Research Square
PI3K signaling-mediated BAP1 O-GlcNAcylation promotes breast cancer malignancy by dual regulation of OGT stability and FOXM1 condensation
Phosphoinositide 3-kinase (PI3K) pathway plays a central role in tumor development and progression, and is frequently activated in human breast cancers. However, the mechanism underlying PI3K-mediated regulation of breast cancer growth and metastasis remains poorly understood. Here we show that the activation of PI3K contributes to breast cancer progression by regulating the downstream OGT ( O -linked N-acetylglucosaminyltransferase)-mediated signaling. Mechanistically, PI3K activation enhances O-GlcNAcylation of BRCA1-associated protein 1 (BAP1), a deubiquitinase of OGT, increasing the association of BAP1 with OGT to suppress proteasomal degradation of OGT. Increased enrichment of OGT at the promoter of genes related to cell proliferation and metastasis subsequently elevates gene expressions to promote breast cancer malignancy. Additionally, OGT-mediated O-GlcNAcylation of oncoprotein forkhead (FKH) box protein M1 (FOXM1) on S394 promotes the biocondensate formation by blocking AMPKα2-mediated S376 phosphorylation, thereby activating oncogenic transcription and accelerating breast cancer progression. Dual blockade of BAP1 and FOXM1 O-GlcNAcylation synergistically impairs breast tumor growth and metastasis in mice. Collectively, our study reveals an important signaling event downstream of PI3K activation to drive breast cancer progression, and suggests new therapeutic avenues for treating patients harboring tumorigenic mutations in the PI3K pathway.
- 10 June 2026
- Published by Springer Nature in Research Square
Open AccessPI3K signaling-mediated BAP1 O-GlcNAcylation promotes breast cancer malignancy by dual regulation of OGT stability and FOXM1 condensation
Phosphoinositide 3-kinase (PI3K) pathway plays a central role in tumor development and progression, and is frequently activated in human breast cancers. However, the mechanism underlying PI3K-mediated regulation of breast cancer growth and metastasis remains poorly understood. Here we show that the activation of PI3K contributes to breast cancer progression by regulating the downstream OGT ( O -linked N-acetylglucosaminyltransferase)-mediated signaling. Mechanistically, PI3K activation enhances O-GlcNAcylation of BRCA1-associated protein 1 (BAP1), a deubiquitinase of OGT, increasing the association of BAP1 with OGT to suppress proteasomal degradation of OGT. Increased enrichment of OGT at the promoter of genes related to cell proliferation and metastasis subsequently elevates gene expressions to promote breast cancer malignancy. Additionally, OGT-mediated O-GlcNAcylation of oncoprotein forkhead (FKH) box protein M1 (FOXM1) on S394 promotes the biocondensate formation by blocking AMPKα2-mediated S376 phosphorylation, thereby activating oncogenic transcription and accelerating breast cancer progression. Dual blockade of BAP1 and FOXM1 O-GlcNAcylation synergistically impairs breast tumor growth and metastasis in mice. Collectively, our study reveals an important signaling event downstream of PI3K activation to drive breast cancer progression, and suggests new therapeutic avenues for treating patients harboring tumorigenic mutations in the PI3K pathway.
- 9 June 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (24) , 25136-25151
A Near-Infrared-Triggered Luminescence-Activated System for In Vivo Biomacromolecular Tagging and Photocatalytic Crosslinking for Large-Scale Investigation of RNA-Protein Complexes in Living Mice
The ability to investigate biomolecular interactions and screen for their therapeutic interventions holds great potential for elucidating biological mechanisms and enabling disease treatment. While photocatalytic cross-linking and tagging systems have emerged as attractive strategies for interrogating biomolecular interactions in cellular contexts, their application in living animals remains challenging due to the limited tissue penetration of UV-vis light. Here, we established a near-infrared (NIR)-triggered biomacromolecule in vivo cross-linking and tagging (IVCT) system based on luminescence-activation-induced photocatalysis using lanthanide-doped upconversion nanoparticles (UCNPs) as energy donors (IVCT-LAUC). IVCT-LAUC converts the deep-tissue penetration 808 nm laser into a 254 nm UV for cross-linking of RNA-protein complexes (RPCs) and simultaneously into 450/650 nm visible light for singlet oxygen (1O2) generation to tag the cross-linked RPCs. This enables second-scale interrogation of dynamic RPCs in living mouse organs using a single excitation source. Enrichment using the tagged handles, followed by sequencing and mass spectrometry analysis, facilitates in vivo capture of RPCs and identification of 1709 and 563 RNA-binding proteins in the mouse kidney and spleen. Our method also supports in vivo off-target evaluation of RPC stabilizers and inhibitors, an application still rarely achieved in the field of drug screening.
- 9 June 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (24) , 25136-25151
A Near-Infrared-Triggered Luminescence-Activated System for In Vivo Biomacromolecular Tagging and Photocatalytic Crosslinking for Large-Scale Investigation of RNA-Protein Complexes in Living Mice
The ability to investigate biomolecular interactions and screen for their therapeutic interventions holds great potential for elucidating biological mechanisms and enabling disease treatment. While photocatalytic cross-linking and tagging systems have emerged as attractive strategies for interrogating biomolecular interactions in cellular contexts, their application in living animals remains challenging due to the limited tissue penetration of UV-vis light. Here, we established a near-infrared (NIR)-triggered biomacromolecule in vivo cross-linking and tagging (IVCT) system based on luminescence-activation-induced photocatalysis using lanthanide-doped upconversion nanoparticles (UCNPs) as energy donors (IVCT-LAUC). IVCT-LAUC converts the deep-tissue penetration 808 nm laser into a 254 nm UV for cross-linking of RNA-protein complexes (RPCs) and simultaneously into 450/650 nm visible light for singlet oxygen (1O2) generation to tag the cross-linked RPCs. This enables second-scale interrogation of dynamic RPCs in living mouse organs using a single excitation source. Enrichment using the tagged handles, followed by sequencing and mass spectrometry analysis, facilitates in vivo capture of RPCs and identification of 1709 and 563 RNA-binding proteins in the mouse kidney and spleen. Our method also supports in vivo off-target evaluation of RPC stabilizers and inhibitors, an application still rarely achieved in the field of drug screening.
- Open Access
- 19 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (29) , 27057-27068
An approach for the systematic profiling of drug-induced remodeling of RNA–RBP (RNA-binding protein) interactions
An integrated approach combining biotinylated furocoumarin probe-mediated RPC enrichment with quantitative proteomics is presented for the profile drug-induced remodeling of RNA–RBP interactions.
- 19 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (29) , 27057-27068
Open AccessAn approach for the systematic profiling of drug-induced remodeling of RNA–RBP (RNA-binding protein) interactions
An integrated approach combining biotinylated furocoumarin probe-mediated RPC enrichment with quantitative proteomics is presented for the profile drug-induced remodeling of RNA–RBP interactions.
- 23 March 2026
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 18 (15) , 3074-3085
An orthogonal extraction workflow for high-depth plasma proteomics with metabolomic compatibility from low microliter-scale samples
An orthogonal extraction workflow enables deep plasma proteome coverage and metabolomic compatibility from only 10 µL plasma, improving low-abundance protein detection while preserving robust metabolite profiling for integrated biomarker discovery.
- 23 March 2026
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 18 (15) , 3074-3085
An orthogonal extraction workflow for high-depth plasma proteomics with metabolomic compatibility from low microliter-scale samples
An orthogonal extraction workflow enables deep plasma proteome coverage and metabolomic compatibility from only 10 µL plasma, improving low-abundance protein detection while preserving robust metabolite profiling for integrated biomarker discovery.
- Open Access
- 1 January 2026
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 16 (1392)
Spatial Proteomics Using S4P
Spatial proteomics enables the mapping of protein distribution within tissues, which is crucial for understanding cellular functions in their native context. While spatial transcriptomics has seen rapid advancement, spatial proteomics faces challenges due to protein non-amplifiability and mass spectrometry sensitivity limitations. This protocol describes a sparse sampling strategy for spatial proteomics (S4P) that combines multi-angle tissue strip microdissection with deep learning–based image reconstruction. The method achieves whole-tissue slice coverage with significantly reduced sampling requirements, enabling mapping of over 9,000 proteins in mouse brain tissue at 525 μm resolution within 200 h of mass spectrometry time. Key advantages include reduced sample processing time, deep proteome coverage, and applicability to centimeter-sized tissue samples.
- 1 January 2026
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 16 (1392)
Open AccessSpatial Proteomics Using S4P
Spatial proteomics enables the mapping of protein distribution within tissues, which is crucial for understanding cellular functions in their native context. While spatial transcriptomics has seen rapid advancement, spatial proteomics faces challenges due to protein non-amplifiability and mass spectrometry sensitivity limitations. This protocol describes a sparse sampling strategy for spatial proteomics (S4P) that combines multi-angle tissue strip microdissection with deep learning–based image reconstruction. The method achieves whole-tissue slice coverage with significantly reduced sampling requirements, enabling mapping of over 9,000 proteins in mouse brain tissue at 525 μm resolution within 200 h of mass spectrometry time. Key advantages include reduced sample processing time, deep proteome coverage, and applicability to centimeter-sized tissue samples.
- Open Access
- 1 September 2025
- Published by China Science Publishing & Media Ltd. in Chinese Journal of Chromatography
- Vol. 43 (9) , 996-1004
A large-scale method for the enrichment and identification of N-glycopeptides in microscale plasma samples
Blood, which forms part of the systemic circulatory system, contains proteins from various tissues and organs. Hence, blood samples are ideal vehicles for studying diseases and physiological states. Plasma is an important component of blood and is essential for clinical proteomics research. Plasma contains rich physiological and pathological information; consequently, it is an ideal medium for discovering disease-related biomarkers. Protein N-glycosylation is a key post-translational modification route. This route is widely involved in biological processes such as intercellular communication, immune regulation, and signal transduction. Changes resulting from aberrant N-glycosylation are closely associated with various pathological conditions, including autoimmune and neurodegenerative diseases and tumors. Hence, N-glycosylation proteomics is highly valuable during biomarker and drug-target development. However, efficiently enriching N-glycopeptides in biological samples before detection by mass spectrometry (MS) is difficult. This is because the highly abundant unmodified peptides result in signal suppression. Consequently, achieving deep N-glycoproteomic coverage is a key challenge, particularly for trace plasma samples, for which in-depth studies are currently lacking. In this study, we developed a strategy for comprehensively profiling trace N-glycopeptides in plasma. This includes an efficient enrichment method in combination with highly sensitive MS. The developed approach integrates glycopeptide enrichment using advanced hydrophilic interaction liquid chromatography (HILIC) with state-of-the-art MS platforms. This significantly enhances detection depth and sensitivity during N-glycosylation analysis using minimal plasma volumes. Selectivity and efficiency during N-glycopeptide enrichment were maximized by systematically optimizing key HILIC-packed stationary-phase parameters. These parameters include chemical composition, pore size, and surface modification. Additionally, the elution gradient was fine-tuned to improve glycopeptide recovery. This optimization process delivered high N-glycopeptide specificity, even in complex plasma matrices. To overcome the limitations of single-platform MS, we implemented a complementary dual-platform strategy. This strategy combines the high-speed, high-resolution capabilities of the Tims TOF Pro 2 instrument with the ultra-high mass accuracy and resolution of the Orbitrap Lumos spectrometer. The former instrument facilitates the rapid and sensitive identification of glycopeptides, particularly for low-abundance species. It exploits the trapped ion mobility spectrometry (TIMS) and parallel accumulated sequential fragmentation (PASEF) technology. The Orbitrap Lumos provides exceptional mass accuracy and high-resolution MS/MS spectra that enable confident glycopeptide structural characterization. This synergistic approach significantly expands the N-glycopeptide identification depth and ensures comprehensive glycosylation-site and glycan-composition coverage. The developed optimized workflow successfully identified 2 962 intact N-glycopeptides using only 20 μg of plasma peptides (equivalent to 0.5 μL of whole plasma). This set a new benchmark for sensitivity in the micro-volume plasma glycoproteome field. This achievement addresses a critical gap, where conventional methods typically require much larger sample volumes. This limits their applicability to clinical and precision medicine settings where sample availability is restricted. The developed platform provides a robust and reliable analytical framework for plasma N-glycoproteomics with significant implications for precision medicine. This method facilitates large-scale clinical studies by enabling highly sensitive glycopeptide profiling from very small plasma volumes. This included the longitudinal monitoring of disease progression and therapeutic responses. Furthermore, it offers a powerful tool for discovering novel N-glycosylation-based biomarkers for use in early disease diagnosis, prognosis, and personalized treatment strategies. In summary, this study advances the technical capabilities of plasma N-glycoproteomics. Additionally, it facilitates the broader use of plasma N-glycoproteomics in biomedical research and clinical diagnostics.
- 1 September 2025
- Published by China Science Publishing & Media Ltd. in Chinese Journal of Chromatography
- Vol. 43 (9) , 996-1004
Open AccessA large-scale method for the enrichment and identification of N-glycopeptides in microscale plasma samples
Blood, which forms part of the systemic circulatory system, contains proteins from various tissues and organs. Hence, blood samples are ideal vehicles for studying diseases and physiological states. Plasma is an important component of blood and is essential for clinical proteomics research. Plasma contains rich physiological and pathological information; consequently, it is an ideal medium for discovering disease-related biomarkers. Protein N-glycosylation is a key post-translational modification route. This route is widely involved in biological processes such as intercellular communication, immune regulation, and signal transduction. Changes resulting from aberrant N-glycosylation are closely associated with various pathological conditions, including autoimmune and neurodegenerative diseases and tumors. Hence, N-glycosylation proteomics is highly valuable during biomarker and drug-target development. However, efficiently enriching N-glycopeptides in biological samples before detection by mass spectrometry (MS) is difficult. This is because the highly abundant unmodified peptides result in signal suppression. Consequently, achieving deep N-glycoproteomic coverage is a key challenge, particularly for trace plasma samples, for which in-depth studies are currently lacking. In this study, we developed a strategy for comprehensively profiling trace N-glycopeptides in plasma. This includes an efficient enrichment method in combination with highly sensitive MS. The developed approach integrates glycopeptide enrichment using advanced hydrophilic interaction liquid chromatography (HILIC) with state-of-the-art MS platforms. This significantly enhances detection depth and sensitivity during N-glycosylation analysis using minimal plasma volumes. Selectivity and efficiency during N-glycopeptide enrichment were maximized by systematically optimizing key HILIC-packed stationary-phase parameters. These parameters include chemical composition, pore size, and surface modification. Additionally, the elution gradient was fine-tuned to improve glycopeptide recovery. This optimization process delivered high N-glycopeptide specificity, even in complex plasma matrices. To overcome the limitations of single-platform MS, we implemented a complementary dual-platform strategy. This strategy combines the high-speed, high-resolution capabilities of the Tims TOF Pro 2 instrument with the ultra-high mass accuracy and resolution of the Orbitrap Lumos spectrometer. The former instrument facilitates the rapid and sensitive identification of glycopeptides, particularly for low-abundance species. It exploits the trapped ion mobility spectrometry (TIMS) and parallel accumulated sequential fragmentation (PASEF) technology. The Orbitrap Lumos provides exceptional mass accuracy and high-resolution MS/MS spectra that enable confident glycopeptide structural characterization. This synergistic approach significantly expands the N-glycopeptide identification depth and ensures comprehensive glycosylation-site and glycan-composition coverage. The developed optimized workflow successfully identified 2 962 intact N-glycopeptides using only 20 μg of plasma peptides (equivalent to 0.5 μL of whole plasma). This set a new benchmark for sensitivity in the micro-volume plasma glycoproteome field. This achievement addresses a critical gap, where conventional methods typically require much larger sample volumes. This limits their applicability to clinical and precision medicine settings where sample availability is restricted. The developed platform provides a robust and reliable analytical framework for plasma N-glycoproteomics with significant implications for precision medicine. This method facilitates large-scale clinical studies by enabling highly sensitive glycopeptide profiling from very small plasma volumes. This included the longitudinal monitoring of disease progression and therapeutic responses. Furthermore, it offers a powerful tool for discovering novel N-glycosylation-based biomarkers for use in early disease diagnosis, prognosis, and personalized treatment strategies. In summary, this study advances the technical capabilities of plasma N-glycoproteomics. Additionally, it facilitates the broader use of plasma N-glycoproteomics in biomedical research and clinical diagnostics.
- 17 July 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (29) , 15855-15863
An Integrated Strategy Using Predicted Spectral Library and Tandem Enrichment for Large-Scale Identification of Low-Abundance Proteins and Intact N-Glycopeptides in Human Plasma
Plasma represents a highly valuable clinical sample for protein biomarker discovery, offering a comprehensive source of physiological and pathological information. N-glycosylation plays key roles in various biological processes and enhances the sensitivity of plasma protein biomarkers for disease diagnosis. Consequently, large-scale characterization of the plasma proteome and N-glycosylation patterns by mass spectrometry (MS) is crucial for identifying biomarkers but remains highly challenging due to three major difficulties. First, plasma protein detection is limited as high-abundance proteins dominate the majority of the MS scans. Second, while plasma proteome coverage can be improved by constructing large-scale empirical spectral libraries and coupling them with DIA-MS, the labor- and time-consuming nature of experimental library generation imposes constraints on its wide adoption in clinical studies. Third, the low concentration and poor ionization of N-glycopeptides make their signals more susceptible to suppression in MS analysis. To address these issues, we developed an integrated workflow applying magnetic graphene-oxide (mGO) nanomaterial enrichment and an in silico predicted spectral library for low-abundance plasma proteome identification, along with tandem enrichment using hydrophilic interaction liquid chromatography (HILIC) for sensitive plasma N-glycoproteome profiling. In this way, 4538 plasma proteins were obtained in a single DIA-MS analysis using a QE-HF mass spectrometer, 10 times more than those obtained from direct analysis of neat plasma. Further HILIC enrichment of the mGO products enabled the identification of 7986 intact N-glycopeptides from 626 proteins with concentrations as low as the nanogram per liter range. Notably, 58.34% of these N-glycopeptides were undetectable by direct HILIC enrichment from neat plasma, highlighting the advantage of applying tandem enrichment.
- 17 July 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (29) , 15855-15863
An Integrated Strategy Using Predicted Spectral Library and Tandem Enrichment for Large-Scale Identification of Low-Abundance Proteins and Intact N-Glycopeptides in Human Plasma
Plasma represents a highly valuable clinical sample for protein biomarker discovery, offering a comprehensive source of physiological and pathological information. N-glycosylation plays key roles in various biological processes and enhances the sensitivity of plasma protein biomarkers for disease diagnosis. Consequently, large-scale characterization of the plasma proteome and N-glycosylation patterns by mass spectrometry (MS) is crucial for identifying biomarkers but remains highly challenging due to three major difficulties. First, plasma protein detection is limited as high-abundance proteins dominate the majority of the MS scans. Second, while plasma proteome coverage can be improved by constructing large-scale empirical spectral libraries and coupling them with DIA-MS, the labor- and time-consuming nature of experimental library generation imposes constraints on its wide adoption in clinical studies. Third, the low concentration and poor ionization of N-glycopeptides make their signals more susceptible to suppression in MS analysis. To address these issues, we developed an integrated workflow applying magnetic graphene-oxide (mGO) nanomaterial enrichment and an in silico predicted spectral library for low-abundance plasma proteome identification, along with tandem enrichment using hydrophilic interaction liquid chromatography (HILIC) for sensitive plasma N-glycoproteome profiling. In this way, 4538 plasma proteins were obtained in a single DIA-MS analysis using a QE-HF mass spectrometer, 10 times more than those obtained from direct analysis of neat plasma. Further HILIC enrichment of the mGO products enabled the identification of 7986 intact N-glycopeptides from 626 proteins with concentrations as low as the nanogram per liter range. Notably, 58.34% of these N-glycopeptides were undetectable by direct HILIC enrichment from neat plasma, highlighting the advantage of applying tandem enrichment.
- Open Access
- 1 May 2025
- Published by China Science Publishing & Media Ltd. in Chinese Journal of Chromatography
- Vol. 43 (5) , 472-486
Research advances of liposomes and exosomes in drug delivery and biomarker screening
Vesicles, are categorized as artificial (i.e., liposomes) or natural (i.e., extracellular vesicles (EVs)) and play significant roles in drug-delivery and biomarker-screening applications. Liposomes, as a representative form of artificial vesicle, are spherical lipid structures composed of one or more artificially synthesized phospholipid bilayers. Liposomes are highly biocompatible and bioavailable, very stable, and easily synthesized; hence, they are among the most commonly used and frequently applied nanocarriers in targeted drug-delivery systems (DDS). EVs are natural small membrane-bound vesicles actively secreted by cells and contain a variety of components, including nucleic acids, proteins, and lipids. They also serve as important mediators of intercellular communication. As the smallest EV subtype, with diameters of only 30-100 nm, exosomes contain unique biomolecules that are considered to be the fingerprints of the parent cells. In the pathological state, the content of exosomes will change; consequently, exosomes are potential disease-diagnosis biomarkers. Recent clinical trials have shown that exosomes are ideal nanocarriers in targeted drug-delivery therapies for a variety of diseases. Compared with traditional artificial liposomal carriers, exosomes display unique advantages and provide the DDS field with new possibilities. Liposomes and exosomes are receiving increasing levels of attention in the drug-delivery and biomarker-screening fields. This article introduces techniques for the preparation of liposomes, and the enrichment and separation of exosomes, and delves into research progress on their use in drug-delivery and biomarker-screening applications. Finally, challenges facing the use of liposomes and exosomes in clinical applications are discussed.
- 1 May 2025
- Published by China Science Publishing & Media Ltd. in Chinese Journal of Chromatography
- Vol. 43 (5) , 472-486
Open AccessResearch advances of liposomes and exosomes in drug delivery and biomarker screening
Vesicles, are categorized as artificial (i.e., liposomes) or natural (i.e., extracellular vesicles (EVs)) and play significant roles in drug-delivery and biomarker-screening applications. Liposomes, as a representative form of artificial vesicle, are spherical lipid structures composed of one or more artificially synthesized phospholipid bilayers. Liposomes are highly biocompatible and bioavailable, very stable, and easily synthesized; hence, they are among the most commonly used and frequently applied nanocarriers in targeted drug-delivery systems (DDS). EVs are natural small membrane-bound vesicles actively secreted by cells and contain a variety of components, including nucleic acids, proteins, and lipids. They also serve as important mediators of intercellular communication. As the smallest EV subtype, with diameters of only 30-100 nm, exosomes contain unique biomolecules that are considered to be the fingerprints of the parent cells. In the pathological state, the content of exosomes will change; consequently, exosomes are potential disease-diagnosis biomarkers. Recent clinical trials have shown that exosomes are ideal nanocarriers in targeted drug-delivery therapies for a variety of diseases. Compared with traditional artificial liposomal carriers, exosomes display unique advantages and provide the DDS field with new possibilities. Liposomes and exosomes are receiving increasing levels of attention in the drug-delivery and biomarker-screening fields. This article introduces techniques for the preparation of liposomes, and the enrichment and separation of exosomes, and delves into research progress on their use in drug-delivery and biomarker-screening applications. Finally, challenges facing the use of liposomes and exosomes in clinical applications are discussed.